Federal Register / Vol. 65, No. 93 / Friday, May 12, 2000 / Notices 30615

Nolte Drive, West Deptford, New Jersey

08066, made application by renewal to

the Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Tetrahydrocannabinols (7370) ...... I

Difenoxin (9168) ........................... I

Propiram (9649) ............................ I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............. II

Methylphenidate (1724) ................ II

Codeine (9050) ............................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................. II

Hydrocodone (9193) ..................... II

Meperidine (9230) ......................... II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

Alfentanil (9737) ............................ II

Sufentanil (9740) .......................... II

Fentanyl (9801) ............................. II

The firm plans to manufacture the

listed controlled substances in bulk to

supply final dosage form manufacturers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 11,

2000.

Dated: May 1, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–11892 Filed 5–11–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on March 21,

2000, Lifepoint, Inc., 10410 Trademark

Street, Rancho Cucamonga, California

91730, made application by renewal to

the Drug Enforcement Administration

(DEA) for the registration as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Tetrahydrocannabinols (7370) ... I

Amphetamine (1100) .................. II

Methamphetamine (1105) .......... II

Phencyclidine (7471) .................. II

Benzoylecgonine (9180) ............ II

Morphine (9300) ......................... II

The firm plans to use gram quantities

of the listed controlled substances to

manufacture drug abuse test kits.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 11,

2000.

Dated: April 21, 2000.

John H. King,

Deputy Assistant Administrator Office of

Diversion Control Drug Enforcement

Administration.

[FR Doc. 00–11888 Filed 5–11–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Important of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substance Import and Export

Act (21 U.S.C. 958(i)), the Attorney

General shall, prior to issuing a

registration under this Section to a bulk

manufacturer of a controlled substance

in Schedule I or II and prior to issuing

a regulation under Section 1002(a)

authorizing the important of such a

substance, provide manufacturers

holding registrations for the bulk

manufacture of the substance an

opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on February 27, 2000,

Lipomed, Inc., One Broadway,

Cambridge, Massachusetts 02142, made

application to the Drug Enforcement

Administration to be registered as an

importer of the basic classes of

controlled substances listed below:

Drug Schedule

Cathinone (1235) .......................... I

Drug Schedule

Methaqualone (2565) ................... I

Lysergic acid diethylamide (7315) I

Marihuana (7360) ......................... I

Tetrahydrocannabinols (7370) ..... I

Mescaline (7381) .......................... I

3,4,5-Trimethoxyamphetamine

(7390).

I

4-Bromo-2, 5-

dimethoxyamphetamine (7391).

I

4-Methy1-2, 5-

dimethoxyamphetamine (7395).

I

2,5-Dimethoxyamphetamine

(7396).

I

2,5-Dimethoxy-4-

ethylamphetamine (7399).

I

3,4-Methylenedioxyamphetamine

(7400).

I

3,4-Methylenedioxy-Nethylamphetamine (7404).I

3,4-

Methylenedioxymethamphetamine (7405).

I

Psilocybin (7437) .......................... I

Psilocyn (7438) ............................. I

Acetyldihydrocodeine (9051) ........ I

Dihydromorphine (9145) ............... I

Heroin (9200) ............................... I

Tilidine (9750) ............................... I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Amobarbital (2125) ....................... II

Secobarbital (2315) ...................... II

Phencyclidine (7471) .................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Dihydroccodeine (9120) ............... II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Hydrocodone (9193) ..................... II

Levorphanol (9220) ...................... II

Methadone (9250) ........................ II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

Oxymorphone (9652) ................... II

Alfentanil (9737) ........................... II

Fentanyl (9801) ............................ II

The firm plans to import small

reference standard quantities of finished

commercial product from its sister

company in Switzerland for sale to its

customers for drug testing and

pharmaceutical research and

development.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

30616 Federal Register / Vol. 65, No. 93 / Friday, May 12, 2000 / Notices

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than June 12, 2000.

This procedure is to be conducted

simultaneously with an independent of

the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import the basic classes

of any controlled substances in

Schedule I or II are and will continue to

be required to demonstrate to the

Deputy Assistant Administrator, Office

of Diversion Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: April 25, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–11885 Filed 5–11–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on January 25,

2000, Mallinckrodt, Inc., Mallinckrodt &

Second Streets, St. Louis, Missouri

63147, made application by renewal to

the Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Tetrahydrocannabinols (7370) ...... I

Dihydromorphine (9145) ............... I

Amphetamine (1100) .................... II

Methylphenidate (1724) ................ II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Diprenorphine (9058) .................... II

Etorphine Hydrochloride (9059) .... II

Dihydrocodeine (9120) ................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................. II

Diphenoxylate (9170) .................... II

Hydrocodone (9193) ..................... II

Levorphanol (9220) ....................... II

Meperidine (9230) ......................... II

Methadone (9250) ........................ II

Methadone-intermediate (9254) ... II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Drug Schedule

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

Opium extracts (9610) .................. II

Opium fluid extract (9620) ............ II

Opium tincture (9630) ................... II

Opium powdered (9639) ............... II

Opium granulated (9640) .............. II

Levo-alphacetylmethadol (9648) .. II

Oxymorphone (9652) .................... II

Noroxymorphone (9668) ............... II

Alfentanil (9737) ............................ II

Sufentanil (9740) .......................... II

Fentanyl (9801) ............................. II

The firm plans to manufacture the

controlled substances for distribution as

bulk products to its customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 11,

2000.

Dated: April 21, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–11889 Filed 5–11–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. 98–34]

Edson W. Redard, M.D., Continuation

of Registration With Restrictions

On June 12, 1998, the Deputy

Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration (DEA) issued an Order

to Show Cause to Edson W. Redard,

M.D. (Respondent) of Sacramento,

California, notifying him of an

opportunity to show cause as to why

DEA should not revoke his DEA

Certificate of Registration BR1670012

and deny any pending applications for

renewal of such registration as a

practitioner pursuant to 21 U.S.C.

823(f), 824(a)(2) and (a)(4).

By letter dated June 26, 1998,

Respondent, through counsel, filed a

request for a hearing, and following

prehearing procedures, a hearing was

held in Sacramento, California on April

27 and 28, 1999, before Administrative

Law Judge Mary Ellen Bittner. At the

hearing both parties called witnesses to

testify and introduced documentary

evidence. After the hearing both parties

submitted proposed findings of fact,

conclusions of law and argument. On

December 20, 1999, Judge Bittner issued

her Opinion and Recommended Ruling,

Findings of Fact, Conclusions of Law

and Decision, recommending that

Respondent’s registration not be

revoked subject to two restrictions.

Neither party filed exceptions to Judge

Bittner’s Opinion and Recommended

Ruling, Findings of Fact, Conclusions of

Law and Decision, and on January 24,

2000, the record was transmitted to the

Deputy Administrator.

The Deputy Administrator has

considered the record in its entirety,

and pursuant to 21 CFR 1316.67, hereby

issues his final order based upon

findings of fact and conclusions of law

as hereinafter set forth. The Deputy

Administrator adopts the Opinion and

Recommended Ruling, Findings of Fact,

Conclusions of Law and Decision of the

Administrative Law Judge, but includes

additional restrictions on Respondent’s

continued registration. His adoption is

in no manner diminished by any

recitation of facts, issues and

conclusions herein, or of any failure to

mention a matter of fact or law.

The Deputy Administrator finds that

Respondent graduated from medical

school in 1987, and in 1991 he began

working as a family practitioner at a

large multi-specialty clinic in

Sacramento, California.

On August 27, 1997, a pharmacist

called the California Department of

Justice, Bureau of Narcotic Enforcement

(BNE) and told an investigator that on

May 20, 1997, Respondent had

presented a prescription in the name of

Donald Gram, for Vicodin ES, a

Schedule III controlled substance. At

that time, Respondent filled out a

patient information form using the name

Donald Gram. The pharmacist had

previously met Respondent when she

worked at another pharmacy, so she

knew that this was not Respondent’s

name. Further investigation revealed

that the address given to the pharmacist

on the patient information form was

Respondent’s address.

The pharmacist told the investigator

that Respondent had presented another

prescription for Vicodin on July 25,

1997, which another pharmacist filled.

The pharmacist further told the

investigator that a pharmacy technician

advised her that Respondent had

presented controlled substance

prescriptions in the name Carol Jordan.